Session Details

S036 A New Paradigm in the Management of the Hidradenitis Suppurativa Disease Spectrum

Sun, Mar 21, 1:00 PM - 4:00 PM
3 CME Available Symposium

DESCRIPTION

This session will provide dermatologists with a complete framework with end-to-end practical decision-making ability to manage patients with HS across the spectrum of disease, inclusive of medical and procedure-based strategies. Discussion of novel concepts in the management of HS supporting this framework will include the following as examples: defining early moderate disease which determines real-world eligibility for targeted treatments; assessing adequacy of initial treatment approach and timing of treatment switches; evaluating for disease progression and remission; choosing off-label strategies having proof of concept to manage recalcitrant disease; and deploying office based procedures to improve symptom control and outcomes.

LEARNING OBJECTIVES

1.

Classify patients with early moderate disease to determine optimal treatment strategy and timing

2.

Describe a practical framework to assess initial treatment adequacy, disease progression, as well as the need and timing to modify therapy

3.

Design a management strategy that incorporates advanced medical therapies, office-based procedures, or sound off-label strategies for progressive or recalcitrant disease

SCHEDULE

1:00 PM

Discussion

DIRECTOR

Amit Garg, MD, FAAD

Amit Garg, MD, FAAD

Northwell Health

SPEAKERS

Falk Bechara

Falk Bechara

Falk G. Bechara, Department of Dermatology, Venereology and Allergology, International Center for Hidradenitis Suppurativa/Acne Inversa (ICH), Ruhr-University Bochum; Germany

John Frew, MBBS, IFAAD

John Frew, MBBS, IFAAD

University of New South Wales, Sydney, Australia

Jennifer Lin Hsiao, MD, FAAD

Jennifer Lin Hsiao, MD, FAAD

Keck School of Medicine, University of Southern California

John Ingram, PhD, MD

John Ingram, PhD, MD

Joslyn S. Kirby, MD, FAAD

Joslyn S. Kirby, MD, FAAD

Penn State Health

DISCLOSURES

Falk Bechara

AbbVie – Advisory Board(Fees); Acelyrin – Other(Fees); Almirall – Other(Fees); Avalo – Other(Fees); Boehringer Ingelheim – Other(Fees); Celltrion – Advisory Board(Fees); Citryll – Other(Fees); Incyte – Other(Fees); Janssen-Cilag – Speaker(Fees); Mölnlycke – Other(Fees); MoonLake Immunotherapeutics – Advisory Board(Fees); Navigator Medicines – Other(Fees); NewBridge Pharmaceuticals – Speaker(Fees); Novartis – Speaker(Fees); Sanofi – Other(Fees); Sitala Bio Ltd – Other(Fees); UCB Pharma – Speaker(Fees);

John Frew, MBBS, IFAAD

Abbvie – Advisory Board(Honoraria); Amgen – Speaker(Honoraria); Apogee – Advisory Board(Honoraria); Avalo Therapeutics Inc – Advisory Board(Honoraria); Behringer-Ingelheim – Advisory Board(Honoraria); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Elasmogen – Advisory Board(Honoraria); JNJ – Advisory Board(Honoraria); Leo Pharma – Advisory Board(Honoraria); MoonLake Immunotherapeutics – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria); Regeneron – Advisory Board(Honoraria);

Amit Garg, MD, FAAD

AbbVie – Advisory Board(Honoraria); Almirall – Consultant (1099 relationship)(Fees); Bluefin Biomedicine – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria); Insmed Incorporated – Consultant (1099 relationship)(Honoraria); Leo Pharma – Advisory Board(Honoraria); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Otsuka Pharmaceutical Co., Ltd. – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Fees); UCB – Consultant(Honoraria); Zura Bio – Consultant (1099 relationship)(Fees);

Jennifer Lin Hsiao, MD, FAAD

AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Avalo – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Insmed – Consultant (1099 relationship)(Fees); Leo Pharma – Consultant (1099 relationship)(Fees); Merck – Consultant (1099 relationship)(Fees); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees), Speaker(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); Spyre Therapeutics – Consultant (1099 relationship)(Fees); UCB – Consultant(Fees), Speaker(Fees);

John Ingram, PhD, MD

AbbVie – Consultant(Honoraria); Bluefin Biomedicine – Consultant (1099 relationship)(Honoraria); Boehringer Ingelheim – Consultant(Honoraria); British Journal of Dermatology – Other(Honoraria); Cantargia – Consultant (1099 relationship)(Honoraria); ChemoCentryx – Consultant(Honoraria); Citryll – Consultant(Honoraria); Elasmogen – Consultant (1099 relationship)(Honoraria); Engitix – Consultant (1099 relationship)(Honoraria); Incyte – Consultant (1099 relationship)(Honoraria); Indero, Inc. – Consultant (1099 relationship)(Honoraria); InflaRx – Consultant (1099 relationship)(Honoraria); Insmed Incorporated – Advisory Board(Honoraria); Kymera Therapeutics – Advisory Board(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Honoraria); Novartis – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); UCB – Consultant(Honoraria); Union Therapeutics – Consultant (1099 relationship)(Honoraria); Viela Bio – Advisory Board(Honoraria);

Joslyn S. Kirby, MD, FAAD

Incyte Corporation – Consultant (1099 relationship)(Fees), Employee (w-2 relationship)(Salary); Penn State University – Other(Patent royalties or other compensation for Intellectual Property Rights);